Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Corinne Cather, Ph.D.

Co-Author

This page shows the publications co-authored by Corinne Cather and A. Evins.
Connection Strength

5.469
  1. Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. CNS Drugs. 2017 Jun; 31(6):471-481.
    View in: PubMed
    Score: 0.712
  2. Improved Depressive Symptoms in Adults with Schizophrenia During a Smoking Cessation Attempt with Varenicline and Behavioral Therapy. J Dual Diagn. 2017 Jul-Sep; 13(3):168-178.
    View in: PubMed
    Score: 0.706
  3. Effective Cessation Strategies for Smokers with Schizophrenia. Int Rev Neurobiol. 2015; 124:133-47.
    View in: PubMed
    Score: 0.632
  4. An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. J Dual Diagn. 2013; 9(1):87-93.
    View in: PubMed
    Score: 0.524
  5. The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis. Child Adolesc Psychiatr Clin N Am. 2020 01; 29(1):145-156.
    View in: PubMed
    Score: 0.210
  6. Smoking cessation in people with serious mental illness. Lancet Psychiatry. 2019 07; 6(7):563-564.
    View in: PubMed
    Score: 0.202
  7. A placebo-controlled randomized trial of D-cycloserine augmentation of cue exposure therapy for smoking cessation. Cogn Behav Ther. 2019 01; 48(1):65-76.
    View in: PubMed
    Score: 0.194
  8. Phase IIb Trial of an a7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence. J Clin Psychopharmacol. 2018 Aug; 38(4):307-316.
    View in: PubMed
    Score: 0.193
  9. Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. Addict Behav. 2017 08; 71:89-95.
    View in: PubMed
    Score: 0.175
  10. A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol. BMC Public Health. 2017 01 19; 17(1):100.
    View in: PubMed
    Score: 0.174
  11. Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder. Schizophr Res. 2017 05; 183:124-129.
    View in: PubMed
    Score: 0.172
  12. Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial. J Clin Psychiatry. 2016 Mar; 77(3):e320-6.
    View in: PubMed
    Score: 0.163
  13. Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices. Harv Rev Psychiatry. 2015 Mar-Apr; 23(2):90-8.
    View in: PubMed
    Score: 0.152
  14. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014 Jan 08; 311(2):145-54.
    View in: PubMed
    Score: 0.141
  15. Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. J Dual Diagn. 2012; 8(2):117-125.
    View in: PubMed
    Score: 0.125
  16. Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry. 2008 Nov; 69(11):1743-50.
    View in: PubMed
    Score: 0.098
  17. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007 Aug; 27(4):380-6.
    View in: PubMed
    Score: 0.090
  18. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry. 2005 Sep; 66(9):1184-90.
    View in: PubMed
    Score: 0.079
  19. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005 Jun; 25(3):218-25.
    View in: PubMed
    Score: 0.077
  20. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004 Mar; 65(3):307-11; quiz 452-3.
    View in: PubMed
    Score: 0.071
  21. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001 Nov; 3(4):397-403.
    View in: PubMed
    Score: 0.060
  22. Developing a Sound Body: Open Trial Results of a Group Healthy Lifestyle Intervention for Young Adults with Psychosis. Community Ment Health J. 2021 07; 57(5):864-871.
    View in: PubMed
    Score: 0.055
  23. Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness: A Randomized Clinical Trial. JAMA Netw Open. 2020 06 01; 3(6):e207247.
    View in: PubMed
    Score: 0.055
  24. Need for Cardiovascular Risk Reduction in Persons With Serious Mental Illness: Design of a Comprehensive Intervention. Front Psychiatry. 2018; 9:786.
    View in: PubMed
    Score: 0.050
  25. Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Ann Clin Psychiatry. 2010 Feb; 22(1):33-42.
    View in: PubMed
    Score: 0.027
  26. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry. 2009 Dec; 70(12):1674-80.
    View in: PubMed
    Score: 0.026
  27. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. J Psychiatr Pract. 2009 Jul; 15(4):251-61.
    View in: PubMed
    Score: 0.026
  28. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009 Apr; 29(2):165-9.
    View in: PubMed
    Score: 0.025
  29. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008 Dec; 106(2-3):320-7.
    View in: PubMed
    Score: 0.024
  30. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl). 2009 Jan; 202(1-3):411-7.
    View in: PubMed
    Score: 0.024
  31. Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Res. 2008 May 30; 159(1-2):140-6.
    View in: PubMed
    Score: 0.024
  32. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophr Res. 2007 Aug; 94(1-3):119-27.
    View in: PubMed
    Score: 0.022
  33. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007 Feb; 115(2):101-5.
    View in: PubMed
    Score: 0.022
  34. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006 May; 67(5):789-97.
    View in: PubMed
    Score: 0.021
  35. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006 Feb; 113(2):142-7.
    View in: PubMed
    Score: 0.020
  36. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2005 Sep; 181(2):358-63.
    View in: PubMed
    Score: 0.020
  37. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005 Sep; 66(9):1116-21.
    View in: PubMed
    Score: 0.020
  38. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005 May; 162(5):954-62.
    View in: PubMed
    Score: 0.019
  39. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005 Feb; 66(2):183-94; quiz 147, 273-4.
    View in: PubMed
    Score: 0.019
  40. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004 Oct; 65(10):1372-6.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.